[Neoadjuvant and adjuvant treatment of pancreatic cancer].

Neoadjuvante und adjuvante Therapie beim Pankreaskarzinom.

Journal

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
ISSN: 1433-0385
Titre abrégé: Chirurg
Pays: Germany
ID NLM: 16140410R

Informations de publication

Date de publication:
Aug 2020
Historique:
pubmed: 18 4 2020
medline: 18 9 2020
entrez: 18 4 2020
Statut: ppublish

Résumé

Resection is the only curative treatment option for pancreatic cancer patients. Adjuvant chemotherapy can improve disease-free survival and overall survival after resection. Furthermore, neoadjuvant treatment protocols are currently being investigated in a large number of studies. Summary of the current evidence for adjuvant and neoadjuvant treatment. Review of the current scientific literature and guidelines. After resection for pancreatic cancer patients should receive intensive chemotherapy with mFOLFIRINOX, gemcitabine plus capecitabine or gemcitabine/5-fluorouracil (5-FU) monotherapy. Neoadjuvant treatment concepts are promising but have to be further evaluated in prospective studies.

Sections du résumé

BACKGROUND BACKGROUND
Resection is the only curative treatment option for pancreatic cancer patients. Adjuvant chemotherapy can improve disease-free survival and overall survival after resection. Furthermore, neoadjuvant treatment protocols are currently being investigated in a large number of studies.
OBJECTIVE OBJECTIVE
Summary of the current evidence for adjuvant and neoadjuvant treatment.
MATERIAL AND METHODS METHODS
Review of the current scientific literature and guidelines.
RESULTS AND CONCLUSION CONCLUSIONS
After resection for pancreatic cancer patients should receive intensive chemotherapy with mFOLFIRINOX, gemcitabine plus capecitabine or gemcitabine/5-fluorouracil (5-FU) monotherapy. Neoadjuvant treatment concepts are promising but have to be further evaluated in prospective studies.

Identifiants

pubmed: 32300820
doi: 10.1007/s00104-020-01169-9
pii: 10.1007/s00104-020-01169-9
doi:

Substances chimiques

Fluorouracil U3P01618RT

Types de publication

Journal Article Review

Langues

ger

Sous-ensembles de citation

IM

Pagination

636-641

Auteurs

C Springfeld (C)

Abteilung Medizinische Onkologie, Nationales Zentrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland. christoph.springfeld@med.uni-heidelberg.de.

T Hackert (T)

Klinik für Allgemein‑, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.

D Jäger (D)

Abteilung Medizinische Onkologie, Nationales Zentrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Deutschland.

M W Büchler (MW)

Klinik für Allgemein‑, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.

J P Neoptolemos (JP)

Klinik für Allgemein‑, Viszeral- und Transplantationschirurgie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH